Recurrent Small Cell Lung Cancer (SCLC) Not Yet Recruiting Phase 2 Trials for Navtemadlin (DB15299)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05027867KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung CancerTreatment